Articles related to TYPE 2 DIABETES

Four major societies jointly published the first multidisciplinary guideline for cardiovascular-kidney-metabolic syndrome, introducing a standardized staging system and unified treatment framework across cardiology, nephrology, endocrinology, and primary care.

A two-sample analysis of GWAS data identified genetically predicted associations between six commonly prescribed medications and increased erectile dysfunction risk, while aspirin did not reach statistical significance after SNP exclusions.

In a 794-patient randomized trial, early-stage type 2 diabetes patients uncontrolled on metformin who received tirzepatide achieved nearly twice the HbA1c reduction of those on intensified conventional care at 2 years, and 60% reached normoglycemia (HbA1c <5.7%), compared to 24% in the ICC arm.

A 2025 AACE consensus statement introduced a complication-centric, staged framework for managing adults with obesity and adiposity-based chronic disease, with drug selection tied to specific obesity-related complications rather than weight loss alone.

The FDA approved inhaled insulin (Afrezza) for pediatric patients aged 6 and older with type 1 or type 2 diabetes, based on phase 3 trial data and long-term safety evidence from manufacturer-sponsored studies.

A retrospective cohort study of 349,168 propensity-matched patients with diabetes found a hazard ratio of 2.22 for nonarteritic anterior ischemic optic neuropathy among semaglutide users compared with non-GLP-1 RA antidiabetic therapy users, with elevated risk emerging at two years and persisting through four years of follow-up.